## FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasiiiigton, D.C. 20045	Washington,	D.C.	20549
-------------------------	-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	PPROVAL								
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*     Sanders Dale									ker or Tra			(Che	5. Relationship of Reporting (Check all applicable) Director V Officer (give title			10% Ow Other (s	/ner	
(Last) (First) (Middle) C/O HEALTH CATALYST, INC. 3165 MILLROCK DRIVE, #400						Date (		iest Tran	saction (N	1onth	/Day/Year)		X below) below)  Chief Technology Officer					
(Street) SALT LA	AKE U	Т	84121		4.1	If Ame	endme	ent, Date	of Original Filed (Month/Day/Year)					6. Individual or Joint/Group Filing (Check Applicat Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person				1
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
, , , , , , , , , , , , , , , , , , ,			2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Disposed O		es Acquired (A) or Of (D) (Instr. 3, 4 and 5		5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	: Direct r Indirect	7. Nature of Indirect Beneficial Ownership			
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock				08/03	/2020	)			М		1,334	A	\$10.8	165	,818	18 D		
Common Stock			08/03	3/2020				М		17,870	A	\$10.3	183	3,688		D		
Common Stock			08/03	/2020	)		М		8,296	A	\$10.3	191	,984		D			
Common Stock			08/03	3/2020				S <sup>(1)</sup>		8,296	D	\$35.19	183,688			D		
Common Stock			08/03	/2020	)			S <sup>(1)</sup>		1,334	D	\$35.19	(2) 182,354			D		
Common Stock			08/03	/2020	)20		S <sup>(1)</sup>		17,870	70 D \$3		(3) 164,484			D			
			Table II						•		oosed of, convertib		-	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ed A	4. Transa Code (I 8)	ction	5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisa	ble	Expiration Date	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$10.8	08/03/2020			М			1,334	(4)		09/27/2028	Common Stock	1,334	\$0.00	470,88	39	D	
Stock Option (Right to	\$10.3	08/03/2020			M			26,166	10/28/20	19 <sup>(5)</sup>	11/09/2025	Common Stock	26,166	\$0.00	0.00		D	

## **Explanation of Responses:**

- 1. The sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 26, 2019, in accordance with Rule 10b5-1.
- 2. Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from \$34.42 to \$35.41, inclusive.
- 3. Represents a weighted average price. These shares were sold by the Reporting Person in multiple transactions at prices ranging from \$35.43 to \$35.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in Footnotes (2) and (3).
- 4. 25% of the 472,223 shares underlying the options vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.
- 5. 25% of the 163,666 shares underlying the options vested in an annual installment and the remaining balance vested in equal monthly installments until the option vested in full on Oct. 28, 2019.

## Remarks:

/s/ Daniel Orenstein, as Attorney-in-Fact

08/05/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.